• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Protein-based vaccine as the booster dose for adults: evidence and beyond.

作者信息

Shang Lianhan, Cao Bin

机构信息

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China; Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China.

出版信息

Lancet Infect Dis. 2022 Nov;22(11):1515-1517. doi: 10.1016/S1473-3099(22)00447-9. Epub 2022 Aug 10.

DOI:10.1016/S1473-3099(22)00447-9
PMID:35963271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9365310/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ea/9365310/dab94eed2ad1/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ea/9365310/dab94eed2ad1/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ea/9365310/dab94eed2ad1/fx1_lrg.jpg

相似文献

1
Protein-based vaccine as the booster dose for adults: evidence and beyond.基于蛋白质的疫苗作为成人加强针：证据及其他。
Lancet Infect Dis. 2022 Nov;22(11):1515-1517. doi: 10.1016/S1473-3099(22)00447-9. Epub 2022 Aug 10.
2
Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.吸附无细胞百白破灭活、全细胞百日咳和破伤风联合疫苗（Boostrix®）：作为单剂加强免疫的特性和用途介绍。
Drugs. 2012 Sep 10;72(13):1765-91. doi: 10.2165/11209630-000000000-00000.
3
Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults.老年人对原发性而非乙型肝炎加强疫苗接种的免疫反应受损。
Front Immunol. 2018 May 15;9:1035. doi: 10.3389/fimmu.2018.01035. eCollection 2018.
4
DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination.DTaP-HBV-IPV/Hib 联合疫苗（百白破-乙肝-脊灰- Hib 联合疫苗）：作为基础和加强免疫接种的应用评价。
Drugs. 2010 May 28;70(8):1021-58. doi: 10.2165/11204830-000000000-00000.
5
[Immune response to one booster dose of inactivated hepatitis A vaccine in college students].[大学生对一剂甲型肝炎灭活疫苗加强针的免疫反应]
Zhonghua Liu Xing Bing Xue Za Zhi. 2017 May 10;38(5):625-628. doi: 10.3760/cma.j.issn.0254-6450.2017.05.013.
6
Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine.在已接种首剂乙肝疫苗的哥斯达黎加儿童中使用白喉-破伤风-百日咳-乙肝/ Hib五价疫苗进行基础免疫和加强免疫。
Rev Panam Salud Publica. 2002 Oct;12(4):247-57. doi: 10.1590/s1020-49892002001000005.
7
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.同源和异源 COVID-19 加强针在接种 1 剂 Ad.26.COV2.S（强生[詹森]）疫苗后的有效性：成人因 COVID-19 前往急诊和紧急护理就诊和住院的情况 - VISION 网络，10 个州，2021 年 12 月至 2022 年 3 月。
MMWR Morb Mortal Wkly Rep. 2022 Apr 1;71(13):495-502. doi: 10.15585/mmwr.mm7113e2.
8
MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.四价脑膜炎球菌结合疫苗加强剂在初免后 4-6 年内接种：一项在青少年和成年人中进行的 IIIb 期、多中心、开放性标签研究的结果。
Vaccine. 2019 Sep 30;37(42):6171-6179. doi: 10.1016/j.vaccine.2019.08.065. Epub 2019 Sep 5.
9
Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.一剂次脑膜炎球菌（A、C、W和Y群）多糖白喉类毒素结合疫苗的安全性和免疫原性
Vaccine. 2016 Oct 17;34(44):5273-5278. doi: 10.1016/j.vaccine.2016.09.003. Epub 2016 Sep 15.
10
Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.联合低抗原含量白喉-破伤风-无细胞百日咳和脊髓灰质炎疫苗（dTpa-IPV）用于成人加强免疫接种。
Vaccine. 2005 May 25;23(28):3657-67. doi: 10.1016/j.vaccine.2005.02.013.

引用本文的文献

1
Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness.基于植物的新冠疫苗作为大流行防范措施出现的紧迫性。
Vaccines (Basel). 2023 Aug 9;11(8):1347. doi: 10.3390/vaccines11081347.

本文引用的文献

1
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.同源加强接种 SARS-CoV-2 重组刺突蛋白疫苗（NVX-CoV2373）的安全性和免疫原性：一项随机、安慰剂对照、2 期临床试验的二次分析。
Lancet Infect Dis. 2022 Nov;22(11):1565-1576. doi: 10.1016/S1473-3099(22)00420-0. Epub 2022 Aug 10.
2
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.奥密克戎 BA.4 和 BA.5 对疫苗和 BA.1 血清的抗体逃逸。
Cell. 2022 Jul 7;185(14):2422-2433.e13. doi: 10.1016/j.cell.2022.06.005. Epub 2022 Jun 9.
3
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
BA.2.12.1、BA.4 和 BA.5 逃避奥密克戎感染诱导的抗体。
Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17.
4
Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.美国 COVID-19 mRNA 疫苗接种后的心肌炎和心包炎风险：索赔数据库中的队列研究。
Lancet. 2022 Jun 11;399(10342):2191-2199. doi: 10.1016/S0140-6736(22)00791-7.
5
Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis.异源和同源 COVID-19 疫苗方案的有效性：基于网络荟萃分析的实时系统评价。
BMJ. 2022 May 31;377:e069989. doi: 10.1136/bmj-2022-069989.
6
Current vaccine strategies against SARS-CoV-2: Promises and challenges.当前针对 SARS-CoV-2 的疫苗策略：前景与挑战。
J Allergy Clin Immunol. 2022 Jul;150(1):17-21. doi: 10.1016/j.jaci.2022.05.008. Epub 2022 May 23.
7
Vaccine-induced immune thrombotic thrombocytopenia (VITT).疫苗诱导的免疫性血栓性血小板减少症（VITT）。
Semin Hematol. 2022 Apr;59(2):57-58. doi: 10.1053/j.seminhematol.2022.03.004. Epub 2022 Mar 8.
8
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.NVX-CoV2373 在美墨成年人群中的疗效和安全性。
N Engl J Med. 2022 Feb 10;386(6):531-543. doi: 10.1056/NEJMoa2116185. Epub 2021 Dec 15.
9
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.在英国（Com-COV2）进行的包含 mRNA、病毒载体和蛋白佐剂疫苗的异源 COVID-19 初级疫苗接种的免疫原性、安全性和反应原性：一项单盲、随机、2 期、非劣效性试验。
Lancet. 2022 Jan 1;399(10319):36-49. doi: 10.1016/S0140-6736(21)02718-5. Epub 2021 Dec 6.
10
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.在英国，用 ChAdOx1 nCov-19 或 BNT162b2 接种两剂后作为第三剂（加强针）接种 7 种 COVID-19 疫苗的安全性和免疫原性（COV-BOOST）：一项盲法、多中心、随机、对照、2 期试验。
Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2.